BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

Affiliations

• ¹ Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
• ² Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR 97239, USA; Howard Hughes Medical Institute, Portland, OR 97239, USA.
• ³ Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA; Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT 84112, USA.
• ⁴ Department of Medicinal Chemistry, College of Pharmacy and The Henry Eyring Center for Theoretical Chemistry, University of Utah, Salt Lake City, UT 84112, USA.
• ⁵ Hematology Department 1F, Centre Hospitalier Lyon Sud, Pierre Bénite, INSERM U1052, CRCL, Lyon 69495, France.
• ⁶ Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA.
• ⁷ University of Chicago, Chicago, IL 60637, USA.
• ⁸ Departments of Leukemia and Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
• ⁹ Department of Medical Oncology and Hematology, Allogeneic Blood and Marrow Transplantation Program, Princess Margaret Hospital, University of Toronto, Toronto ON M5G 2M9, Canada.
• ¹⁰ Service des Maladies du Sang, Hospital Saint-Louis, 75010 Paris, France.
• ¹¹ Department of Hematology, Karolinska Institutet and University Hospital, 17176 Stockholm, Sweden.
• ¹² Department of Molecular Medicine and Surgery, Karolinska Institutet, 17176 Stockholm, Sweden.
• ¹³ Hematology and Oncology, University of Leipzig, 04103 Leipzig, Germany.
• ¹⁴ Hematology and Medical Oncology Department, Hospital Clínico Universitario, 46010 Valencia, Spain.
• ¹⁵ Department of Hematology, VU University Medical Center, Amsterdam 1081HV, the Netherlands.
• ¹⁶ Department of Pathology and Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.
• ¹⁷ Department of Hematology, Singapore General Hospital, Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, 169856 Singapore, Singapore.
• ¹⁸ John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ 07601, USA.
• ¹⁹ Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
• ²⁰ Laboratoire d'Hematologie, Centre Hospitalier Universitaire de Bordeaux and Laboratoire Hematopoïese Leucemique et Cible Therapeutique, Inserm U1035, Universite Bordeaux, 33076 Bordeaux, France.
• ²¹ Departement d'Oncologie Medicale, Centre Regional de Lutte Contre le Cancer de Bordeaux et du Sud-Ouest, Institut Bergonie, 33076 Bordeaux, France.
• ²² Department of Experimental, Diagnostic, and Specialty Medicine, Institute of Hematology "L. e A. Seràgnoli," University of Bologna, 40138 Bologna, Italy.
• ²³ Service d'Hématologie et d'Oncologie, Université de Versailles, 75010 Paris, France.
• ²⁴ Department of Chemistry and Biomedical Sciences and Centre for Biomaterials Chemistry, Linnaeus University, 391 82 Kalmar, Sweden.
• ²⁵ Department of Pathology, University of Utah, Salt Lake City, UT 84112, USA.
• ²⁶ Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA; Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT 84112, USA. Electronic address: [email protected].
• ²⁷ Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA; Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT 84112, USA. Electronic address: [email protected].